Coronavirus: Vaccination

(asked on 28th January 2021) - View Source

Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will make an assessment of the potential merits of negotiating an amendment to his contract with Oxford-AstraZeneca to change its emphasis on providing vaccines on only a non-profit basis to make provision for a suitable premium for each additional dose provided in advance of agreed delivery schedules.


Answered by
Nadhim Zahawi Portrait
Nadhim Zahawi
This question was answered on 2nd February 2021

Details of negotiations between the Government and vaccine developers are commercially confidential. The Government robustly negotiated with suppliers to ensure the best possible terms in order to ensure access to safe and effective vaccines as soon as possible. Through this approach, the Government has secured early access to 407 million vaccines doses through agreements with seven vaccine developers – this includes 100 million doses of the AstraZeneca/Oxford vaccine.

The UK was the first country in the world to procure, authorise and then deploy both the Oxford University/AstraZeneca and Pfizer/BioNTech vaccines.

The UK vaccine supply and scheduled deliveries will fully support vaccination of priority cohorts 1 to 4, as advised by the Joint Committee on Vaccination and Immunisation, and we are on track to offer a first vaccine to every person in these cohorts by 15 February 2021.

Reticulating Splines